Further investigation into the pathophysiology and management of dpAEs is warranted to ensure optimal therapy and improve patients’ quality of life.^[17] By understanding the pathogenesis and clinical manifestations of these AEs, dermatologists play a critical role in guiding oncologic therapy by minimizing unwarranted dose reduction and dose stoppage.^[17]

This case report is valuable due to the rarity of hyperpigmentation description in literature associated with imatinib mesylate therapy. Thus, this uncommon side effect needs to recognised early and managed appropriately . As imatinib therapy is very crucial in CML, its interruption after the development of this adverse effect is not mandatory or recommended. We conclude that Informing the patient about the possibility of this side effect can increase compliance to therapy.Further insight into the mechanisms of the pigmentary alterations caused by this drug is required for better treatment/prevention of this manifestation. .

I was very worried at first when I came to know about my disease. I was supported by my family for treatment. The doctors were very good and they helped me in overcoming this disease and also counselled me about this reaction and its management. But I am comfortable now because I am experiencing symptomatic relief from my native disease and also this side effect. I am very thankful to my doctors to prolong my life .

Written informed consent was obtained from the patient for publication of the present manuscript, including the medical data and any accompanying images.

1. Li CC, Malik SM, Blaeser BF, Dehni WJ, Kabani SP, Boyle N, et al. Mucosal pigmentation caused by imatinib: report of three cases. Head Neck Pathol. 2012;6:290–5. [PMC-free article] [PubMed] [Google Scholar]

2. Kagimoto Y, Mizuashi M, Kikuchi K, Aiba S. Lichenoid drug eruption with hyperpigmentation caused by imatinib mesylate. Int J Dermatol. 2014;53:e161–2. [PubMed] [Google Scholar]

3. Balasubramanian P, Jagadeesan S, Thomas J. Imatinib-induced Extensive Hyperpigmentation in a Case of Chronic Myeloid Leukemia. Indian J Dermatol. 2015 Sep-Oct;60(5):523. doi: 10.4103/0019-5154.164447

4. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients. J Am Acad Dermatol. 2003;48:201–6. [PubMed] [Google Scholar]

5. Prabhash K, Ghanshyam B, Prasad N, Karant N, Sastry PS, Parikh PM. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia. Indian J Dermatol Venerol Leprol. 2006;72:63–4. [PubMed] [Google Scholar]

6. Singh N, Bakshi S. Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia. J Pediatr Hematol Oncol. 2007;29:208–9. [PubMed] [Google Scholar]

7. Prasad N, Deshmukh C, Biswas G, Bakshi A, Sastry PS, Parikh PM. Dermatological toxicity of Imatinib mesylate. J Assoc Physicians India. 2005;53:298. [PubMed] [Google Scholar]

8 .Hamza I, Gaies E, Kastalli E, Daghfous R, El Aidli S. Facial hyperpigmentation during Imatinib therapy for gastrointestinal stromal tumor. Therapie. 2014;69(3):245–[PubMed] [Google Scholar]

9.Balagula Y, Pulitzer MP, Maki RG, Mysfowski PL. Pigmentary changes in a patient treated with imatinib. J Drugs Dermatol 2011;10:1062-6.[Google Scholar]

10. Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 2004;15:358-9.[Google Scholar]

11. Mcpherson T, Sherman V, Turner R. Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol 2009;23:82-3.

12. Mattson U, Halbritter S, Morner Serikoff E, Christerson L, Warfvinge G. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: A report of three cases. Oral Surg Oral Med Pathol Oral Radiol Endod 2011;111:12-6.[Google Scholar]

14. Ghunawat S, Sarkar R, Garg VK. Imatinib induced melasma-like pigmentation: Report of five cases and review of literature. Indian J Dermatol Venereol Leprol 2016;82:409-41252.

15. Khoo TL, Catalano A, Supple S, Chong L, Yeoh SC, Yeung S, et al. Hyperpigmentation of the hard palate associated with Imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT. Leuk Lymphoma. 2013;54(1):186–8. [PubMed] [Google Scholar]

16. Peuvrel L, Quereux G, Brocard A, Saint-Jean M, Dreno B. Onychopathy induced by Temsirolimus, a mammalian target of rapamycin inhibitor. Dermatology. 2012;224:204–8. [PubMed] [Google Scholar]

17.Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. J Am Acad Dermatol. 2017 Nov;77(5):902-910.e2. doi: 10.1016/j.jaad.2017.06.044. Epub 2017 Sep 14. PMID: 28918974; PMCID: PMC5657394

18 Di Tullio F, Mandel VD, Scotti R, Padalino C, Pellacani G, et al. Imatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature. Int J Dermatol. 2018. doi: 10.1111/ijd.13931